FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jim Tartaglia

Research Profile

Living Beings

Chemicals & Drugs

Anatomy

T-Lymphocytes, Cytotoxic

Disorders

Procedures

Co-author Network

Publications

TOP 3
Supachai Rerks-Ngarm; Merlin L Robb; Jim Tartaglia; Prasert Thongcharoen; Rapee Trichavaroj; Elizabeth Adams; Charla Andrews; Chureeratana Bowonwatanuwong; Supamit Chunsutthiwat; Nampueng Churikanont; Mark de Souza; Chirapa Eamsila; Jorge Flores; Donald Francis; Peter B Gilbert; Sanjay Gurunathan; Jaranit Kaewkungkal; Prayura Kunasol; Shuying S Li; Nelson L Michael; Chawetsan Namwat; Viseth Ngauy; Sorachai Nitayaphan; Robert J O'Connell; Robert M Paris; Nakorn Premsri; Jerome H Kim
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
Poonam Pegu; Mangala Rao; Donald Stablein; Jim Tartaglia; Georgia D Tomaras; Monica Vaccari; David Venzon; Stephen Whitney; Shari Gordon; Yongjun Guan; Lauren Hudacik; Brandon F Keele; Jerome Kim; Jeffrey D Lifson; Nelson Michael; David Montefiori; Ranajit Pal; S Munir Alam; Erik Billings; Melvin Doster; Claudio Fenizia; Guido Ferrari; Maria Grazia Ferrari; Genoveffa Franchini
Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial.
Merlin L Robb; Don Stablein; Jim Tartaglia; Prasert Thongcharoen; Prayura Kunasol; Nelson L Michael; Patricia Morgan; Sorachai Nitayaphan; Robert M Paris; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Elizabeth Adams; Michael Benenson; Joseph Chiu; Donald Francis; Peter Gilbert; Sanjay Gurunathan; Jaranit Kaewkungwal; Chirasak Khamboonruang; Jerome H Kim
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jim Tartaglia (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Supachai Rerks-Ngarm; Merlin L Robb; Jim Tartaglia; Prasert Thongcharoen; Rapee Trichavaroj; Elizabeth Adams; Charla Andrews; Chureeratana Bowonwatanuwong; Supamit Chunsutthiwat; Nampueng Churikanont; Mark de Souza; Chirapa Eamsila; Jorge Flores; Donald Francis; Peter B Gilbert; Sanjay Gurunathan; Jaranit Kaewkungkal; Prayura Kunasol; Shuying S Li; Nelson L Michael; Chawetsan Namwat; Viseth Ngauy; Sorachai Nitayaphan; Robert J O'Connell; Robert M Paris; Nakorn Premsri; Jerome H Kim
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
The Journal of infectious diseases 2013;207(8):1195-205.
2013: Poonam Pegu; Mangala Rao; Donald Stablein; Jim Tartaglia; Georgia D Tomaras; Monica Vaccari; David Venzon; Stephen Whitney; Shari Gordon; Yongjun Guan; Lauren Hudacik; Brandon F Keele; Jerome Kim; Jeffrey D Lifson; Nelson Michael; David Montefiori; Ranajit Pal; S Munir Alam; Erik Billings; Melvin Doster; Claudio Fenizia; Guido Ferrari; Maria Grazia Ferrari; Genoveffa Franchini
Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial.
Journal of virology 2013;87(3):1708-19.
2012: Merlin L Robb; Don Stablein; Jim Tartaglia; Prasert Thongcharoen; Prayura Kunasol; Nelson L Michael; Patricia Morgan; Sorachai Nitayaphan; Robert M Paris; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Elizabeth Adams; Michael Benenson; Joseph Chiu; Donald Francis; Peter Gilbert; Sanjay Gurunathan; Jaranit Kaewkungwal; Chirasak Khamboonruang; Jerome H Kim
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.
The Lancet infectious diseases 2012;12(7):531-7.
2011: Matthieu Perreau; Jim Tartaglia; Ralf Wagner; Hugh C Welles; Pierre-Alexandre Bart; Gian Dorta; Mariano Esteban; Olivia Hall; Alexandre Harari; Eric J Kremer; Yves Levy; Michel Maillard; Ricardo Martin; Giuseppe Pantaleo
DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa.
Journal of virology 2011;85(19):9854-62.
2010: Andrew J Bett; Sheri A Dubey; Devan V Mehrotra; Liming Guan; Romnie Long; Kiersten Anderson; Kelly Collins; Christine Gaunt; Rose Fernandez; Suzanne Cole; Steve Meschino; Aimin Tang; Xiao Sun; Sanjay Gurunathan; Jim Tartaglia; Michael N Robertson; John W Shiver; Danilo R Casimiro
Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans.
Vaccine 2010;28(50):7881-9.
2009: Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.
The New England journal of medicine 2009;361(23):2209-20.
2008: Sheena McCormack; Wolfgang Stöhr; Tristan Barber; Pierre-Alexandre Bart; Alexandre Harari; Christiane Moog; Donatella Ciuffreda; Cristina Cellerai; Miranda Cowen; Romilda Gamboni; Séverine Burnet; Ken Legg; Elizabeth Brodnicki; Hans Wolf; Ralf Wagner; Jonathan Luke Heeney; Marie-Joëlle Frachette; Jim Tartaglia; Abdel G Babiker; Giuseppe Pantaleo; Jonathan Weber
EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone.
Vaccine 2008;26(25):3162-74.
2008: Alexandre Harari; Pierre-Alexandre Bart; Wolfgang Stöhr; Gonzalo Tapia; Miguel Garcia; Emmanuelle Medjitna-Rais; Séverine Burnet; Cristina Cellerai; Otto Erlwein; Tristan Barber; Christiane Moog; Peter Liljestrom; Ralf Wagner; Hans Wolf; Jean-Pierre Kraehenbuhl; Mariano Esteban; Jonathan Luke Heeney; Marie-Joelle Frachette; Jim Tartaglia; Sheena McCormack; Abdel Babiker; Jonathan Weber; Giuseppe Pantaleo
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.
The Journal of experimental medicine 2008;205(1):63-77.
2007: Xiugen Zhang; Farah Cassis-Ghavami; Michael A Eller; Jeff Currier; Bonnie M Slike; Xuemin Chen; Jim Tartaglia; Mary A Marovich; Paul Spearman
Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors.
Journal of virology 2007;81(13):7022-33.
2006: Ranajit Pal; David Venzon; Sampa Santra; Vaniambadi S Kalyanaraman; David C Montefiori; Lindsey Hocker; Lauren Hudacik; Nicolas Rose; Janos Nacsa; Yvette Edghill Spano; Marcin Moniuszko; Zdenek Hel; Igor M Belyakov; Jay A Berzofsky; Robyn Washington Parks; Phillip D Markham; Norman L Letvin; Jim Tartaglia; Genoveffa Franchini
Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.
Journal of virology 2006;80(8):3732-42.
2006: Zdenek Hel; Wen-Po Tsai; Elzbieta Tryniszewska; Janos Nacsa; Phillip D Markham; Mark G Lewis; George Pavlakis; Barbara K Felber; Jim Tartaglia; Genoveffa Franchini
Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(1):85-96.
2005: Nicolas van Baren; Marie-Claude Bonnet; Brigitte Dréno; Amir Khammari; Thierry Dorval; Sophie Piperno-Neumann; Danielle Liénard; Daniel Speiser; Marie Marchand; Vincent G Brichard; Bernard Escudier; Sylvie Négrier; Pierre-Yves Dietrich; Dominique Maraninchi; Susanne Osanto; Ralf G Meyer; Gerd Ritter; Philippe Moingeon; Jim Tartaglia; Pierre van der Bruggen; Pierre G Coulie; Thierry Boon
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(35):9008-21.
2005: Xuemin Chen; Michael T Rock; Jason Hammonds; Jim Tartaglia; Ayumi Shintani; Jeff Currier; Bonnie M Slike; James Crowe; Mary A Marovich; Paul Spearman
Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses.
Journal of virology 2005;79(9):5537-47.
2005: Chitraporn Karnasuta; Robert M Paris; Josephine H Cox; Sorachai Nitayaphan; Punnee Pitisuttithum; Prasert Thongcharoen; Arthur E Brown; Sanjay Gurunathan; Jim Tartaglia; William L Heyward; John G McNeil; Deborah L Birx; Mark de Souza
Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand.
Vaccine 2005;23(19):2522-9.
2005: Michael R Betts; Barbara Exley; David A Price; Anju Bansal; Zenaido Tres Camacho; Vanessa Teaberry; Sadie M West; David R Ambrozak; Georgia D Tomaras; Mario Roederer; J. Michael Kilby; Jim Tartaglia; Robert B Belshe; Feng Gao; Daniel C Douek; Kent J Weinhold; Richard A Koup; Paul A Goepfert; Guido Ferrari
Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(12):4512-7.
2005: Koen K A Van Rompay; Kristina Abel; Jonathan R Lawson; Raman P Singh; Kimberli A Schmidt; Thomas Evans; Patricia Earl; Danielle Harvey; Genoveffa Franchini; Jim Tartaglia; David Montefiori; Shilpa Hattangadi; Bernard Moss; Marta L Marthas
Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV.
Journal of acquired immune deficiency syndromes (1999) 2005;38(2):124-34.
2005: John A Tine; Hueseyin Firat; Anne Payne; Guy Russo; Stephen W Davis; Jim Tartaglia; François A Lemonnier; Pierre Langlade Demoyen; Philippe Moingeon
Enhanced multiepitope-based vaccines elicit CD8+ cytotoxic T cells against both immunodominant and cryptic epitopes.
Vaccine 2005;23(8):1085-91.
2004: Danilo R Casimiro; Andrew J Bett; Tong-Ming Fu; Mary-Ellen Davies; Aimin Tang; Keith A Wilson; Minchun Chen; Romnie Long; Troy W McKelvey; Michael A Chastain; Sanjay Gurunathan; Jim Tartaglia; Emilio A Emini; John W Shiver
Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors.
Journal of virology 2004;78(20):11434-8.
2004: Genoveffa Franchini; Sanjay Gurunathan; Lynn Baglyos; Stanley Plotkin; Jim Tartaglia
Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors.
Expert review of vaccines 2004;3(4 Suppl):S75-88.
2004: Guido Ferrari; Wesley Neal; Janet Ottinger; Anizsa M Jones; Bradley H Edwards; Paul A Goepfert; Michael R Betts; Richard A Koup; Susan Buchbinder; M Juliana McElrath; Jim Tartaglia; Kent J Weinhold
Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele.
Journal of immunology (Baltimore, Md. : 1950) 2004;173(3):2126-33.
2004: Janos Nacsa; Antonia Radaelli; Yvette Edghill Spano; David Venzon; Wen-Po Tsai; Carlo De Giuli Morghen; Dennis Panicali; Jim Tartaglia; Genoveffa Franchini
Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques.
Vaccine 2004;22(5-6):597-606.
2003: T-M Jourdier; C Moste; Marie-Claude Bonnet; Françoise Delisle; J-P Tafani; Patrick Devauchelle; Jim Tartaglia; Philippe Moingeon
Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2).
Gene therapy 2003;10(26):2126-32.
2003: Yvette Edghill Spano; David Venzon; Tatiana S Karpova; James McNally; Janos Nacsa; Wen-Po Tsai; Elzbieta Tryniszewska; Marcin Moniuszko; Jody Manischewitz; Lisa R King; Steven J Snodgrass; John Parrish; Phillip Markham; Marsha Sowers; Derrick Martin; Mark G Lewis; Jay A Berzofsky; Igor M Belyakov; Bernard Moss; Jim Tartaglia; Mike Bray; Vanessa M Hirsch; Hana Golding; Genoveffa Franchini
Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques.
The Journal of infectious diseases 2003;188(8):1181-91.
2002: Zdenek Hel; Janos Nacsa; Wen-Po Tsai; Arthur Thornton; Laura Giuliani; Jim Tartaglia; Genoveffa Franchini
Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques.
Virology 2002;304(1):125-34.
2002: Elzbieta Tryniszewska; Janos Nacsa; Mark G Lewis; Peter Silvera; David Montefiori; David Venzon; Zdenek Hel; Robyn Washington Parks; Marcin Moniuszko; Jim Tartaglia; Kendall A Smith; Genoveffa Franchini
Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(9):5347-57.
2002: Zdenek Hel; Janos Nacsa; Elzbieta Tryniszewska; Wen-Po Tsai; Robyn Washington Parks; David C Montefiori; Barbara K Felber; Jim Tartaglia; George Pavlakis; Genoveffa Franchini
Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(9):4778-87.
2002: Liljana Stevceva; Xavier Alvarez; Andrew Lackner; Elzbieta Tryniszewska; Brian Kelsall; Janos Nacsa; Jim Tartaglia; Warren Strober; Genoveffa Franchini
Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques.
Journal of virology 2002;76(22):11659-76.
2002: Zdenek Hel; Elzbieta Tryniszewska; Wen-Po Tsai; Julie M Johnson; Robert Harrod; Jake R Fullen; Vaniambadi S Kalyanaraman; John D Altman; James McNally; Tatiana S Karpova; Barbara K Felber; Jim Tartaglia; Genoveffa Franchini
Design and in vivo immunogenicity of a polyvalent vaccine based on SIVmac regulatory genes.
DNA and cell biology 2002;21(9):619-26.
2002: Zdenek Hel; Julie M Johnson; Elzbieta Tryniszewska; Wen-Po Tsai; Robert Harrod; Jake R Fullen; Jim Tartaglia; Genoveffa Franchini
A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine.
Vaccine 2002;20(25-26):3171-86.
2002: Ranajit Pal; David Venzon; Norman L Letvin; Sampa Santra; David C Montefiori; Neil R Miller; Elzbieta Tryniszewska; Mark G Lewis; Thomas C VanCott; Vanessa M Hirsch; ruth woodward; A Gibson; M Grace; E Dobratz; Phillip D Markham; Zdenek Hel; Janos Nacsa; M Klein; Jim Tartaglia; Genoveffa Franchini
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.
Journal of virology 2002;76(1):292-302.
2001: Z Y Fang; K Limbach; Jim Tartaglia; Jason Hammonds; Xuemin Chen; Paul Spearman
Expression of vaccinia E3L and K3L genes by a novel recombinant canarypox HIV vaccine vector enhances HIV-1 pseudovirion production and inhibits apoptosis in human cells.
Virology 2001;291(2):272-84.
2001: Zdenek Hel; Wen-Po Tsai; A Thornton; Janos Nacsa; Laura Giuliani; Elzbieta Tryniszewska; M Poudyal; David Venzon; X Wang; John D Altman; David Ian Watkins; Wuyuan Lu; Agneta S von Gegerfelt; Barbara K Felber; Jim Tartaglia; George Pavlakis; Genoveffa Franchini
Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen.
Journal of immunology (Baltimore, Md. : 1950) 2001;167(12):7180-91.
2001: Iris Motta; F André; Annick Lim; Jim Tartaglia; W I Cox; L Zitvogel; E Angevin; Philippe Kourilsky
Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells.
Journal of immunology (Baltimore, Md. : 1950) 2001;167(3):1795-802.
2001: F Boudet; M Chevalier; T M Jourdier; Jim Tartaglia; C Moste
Modulation of the antibody response to the HIV envelope subunit by co-administration of infectious or heat-inactivated canarypoxvirus (ALVAC) preparations.
Vaccine 2001;19(30):4267-75.
2001: David C Montefiori; Jeffrey T Safrit; Shari L Lydy; Ashley P Barry; Miroslawa Bilska; H T Vo; M Klein; Jim Tartaglia; Harriet L Robinson; B Rovinski
Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.
Journal of virology 2001;75(13):5879-90.
2001: Suryaprakash Sambhara; A Kurichh; R Miranda; O James; BJ Underdown; M Klein; Jim Tartaglia; D Burt
Severe impairment of primary but not memory responses to influenza viral antigens in aged mice: costimulation in vivo partially reverses impaired primary immune responses.
Cellular immunology 2001;210(1):1-4.
2001: Jim Tartaglia; Marie-Claude Bonnet; Neil L Berinstein; B Barber; M Klein; Philippe Moingeon
Therapeutic vaccines against melanoma and colorectal cancer.
Vaccine 2001;19(17-19):2571-5.
2001: Brigitte Rosenwirth; EM Kuhn; Jonathan Luke Heeney; C Hurpin; Jim Tartaglia; Marie-Claude Bonnet; Philippe Moingeon; LF Erdile
Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the intravenous route in rhesus macaques.
Vaccine 2001;19(13-14):1661-70.
2001: L Odin; Marie-Christine Favrot; D Poujol; J P Michot; Philippe Moingeon; Jim Tartaglia; Isabelle Puisieux
Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53.
Cancer gene therapy 2001;8(2):87-98.
2000: R Bures; Alicia Gaitan; T Zhu; C Graziosi; Kevin M McGrath; Jim Tartaglia; P Caudrelier; Raphaelle El Habib; M Klein; Adriano Lazzarin; Donald Stablein; Mark Deers; Lawrence Corey; ML Greenberg; David H Schwartz; David C Montefiori
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
AIDS research and human retroviruses 2000;16(18):2019-35.
2000: L Jean Patterson; Bo Peng; Alash'Le Abimiku; Kristine Aldrich; L Murty; Phillip D Markham; Vaniambadi S Kalyanaraman; W Gregory Alvord; Jim Tartaglia; Genoveffa Franchini; Marjorie Robert-Guroff
Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaques.
AIDS (London, England) 2000;14(16):2445-55.
2000: Zdenek Hel; David Venzon; M Poudyal; Wen-Po Tsai; Laura Giuliani; ruth woodward; Claire Chougnet; G Shearer; John D Altman; D Watkins; Norbert Bischofberger; Alash'Le Abimiku; Phillip Markham; Jim Tartaglia; Genoveffa Franchini
Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques.
Nature medicine 2000;6(10):1140-6.
2000: Marie-Claude Bonnet; Jim Tartaglia; F Verdier; P Kourilsky; A Lindberg; M Klein; Philippe Moingeon
Recombinant viruses as a tool for therapeutic vaccination against human cancers.
Immunology letters 2000;74(1):11-25.
2000: J Welter; J Taylor; Jim Tartaglia; E Paoletti; Charles B Stephensen
Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines.
Journal of virology 2000;74(14):6358-67.
1999: Thomas G Evans; Michael C Keefer; Kent J Weinhold; Mark Wolff; David Montefiori; Geoffrey J Gorse; Barney S Graham; M Juliana McElrath; Mary Lou Clements-Mann; Mark MULLIGAN; Patricia Fast; MC Walker; Jean-Louis Excler; AM Duliege; Jim Tartaglia
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.
The Journal of infectious diseases 1999;180(2):290-8.
1999: Dominique Salmon-Céron; Jean-Louis Excler; Laurent Finkielsztejn; Brigitte Autran; J C Gluckman; Didier Sicard; TJ Matthews; B Meignier; C Valentin; Raphaelle El Habib; C Blondeau; M Raux; Christiane Moog; Jim Tartaglia; P Chong; M Klein; B Milcamps; F Heshmati; Stanley Plotkin
Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.
AIDS research and human retroviruses 1999;15(7):633-45.
1999: Michel Leno; L Carter; D J Venzon; J Romano; Phillip D Markham; K Limbach; Jim Tartaglia; E Paoletti; J Benson; Genoveffa Franchini; Marjorie Robert-Guroff
CD8+ lymphocyte antiviral activity in monkeys immunized with SIV recombinant poxvirus vaccines: potential role in vaccine efficacy.
AIDS research and human retroviruses 1999;15(5):461-70.
1999: J Welter; J Taylor; Jim Tartaglia; E Paoletti; Charles B Stephensen
Mucosal vaccination with recombinant poxvirus vaccines protects ferrets against symptomatic CDV infection.
Vaccine 1999;17(4):308-18.
1999: J Arp; B Rovinski; Suryaprakash Sambhara; Jim Tartaglia; Gregory A Dekaban
Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions.
Viral immunology 1999;12(4):281-96.
1998: Robert B Belshe; Geoffrey J Gorse; Mark MULLIGAN; Thomas G Evans; Michael C Keefer; Jean-Louis Excler; AM Duliege; Jim Tartaglia; W I Cox; James McNamara; K L Hwang; A Bradney; David Montefiori; Kent J Weinhold
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
AIDS (London, England) 1998;12(18):2407-15.
1998: Isabelle Puisieux; L Odin; D Poujol; Philippe Moingeon; Jim Tartaglia; W Cox; Marie-Christine Favrot
Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity.
Human gene therapy 1998;9(17):2481-92.
1998: Jim Tartaglia; Jean-Louis Excler; Raphaelle El Habib; K Limbach; B Meignier; Stanley Plotkin; M Klein
Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV.
AIDS research and human retroviruses 1998;14 Suppl 3():S291-8.
1998: S T Shors; E Beattie; E Paoletti; Jim Tartaglia; Bertram L Jacobs
Role of the vaccinia virus E3L and K3L gene products in rescue of VSV and EMCV from the effects of IFN-alpha.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1998;18(9):721-9.
1998: Mary Lou Clements-Mann; Kent J Weinhold; TJ Matthews; Barney S Graham; Geoffrey J Gorse; Michael C Keefer; M Juliana McElrath; RH Hsieh; Jiri Mestecky; Susan Zolla-Pazner; J Mascola; David H Schwartz; Robert Siliciano; Lawrence Corey; Peter F Wright; Robert B Belshe; Raphael Dolin; S Jackson; S Xu; Patricia Fast; MC Walker; Donald Stablein; Jean-Louis Excler; Jim Tartaglia; E Paoletti
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
The Journal of infectious diseases 1998;177(5):1230-46.
1998: J Benson; Claire Chougnet; Marjorie Robert-Guroff; David Montefiori; Phillip Markham; G Shearer; Robert C Gallo; Martin Cranage; E Paoletti; K Limbach; David Venzon; Jim Tartaglia; Genoveffa Franchini
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.
Journal of virology 1998;72(5):4170-82.
1998: C Hurpin; C Rotarioa; H Bisceglia; M Chevalier; Jim Tartaglia; LF Erdile
The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity.
Vaccine 1998;16(2-3):208-15.
1998: MC Tellier; Ruiyu Pu; D Pollock; A Vitsky; Jim Tartaglia; E Paoletti; Janet K Yamamoto
Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
AIDS (London, England) 1998;12(1):11-8.
1997: E Coëffier; Jean-Louis Excler; Marie Paule Kieny; B Meignier; C Moste; Jim Tartaglia; Gilles Pialoux; Dominique Salmon-Céron; CLAUDE LECLERC
Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccines.
AIDS research and human retroviruses 1997;13(17):1471-85.
1997: Guido Ferrari; C Berend; Janet Ottinger; Richard K Dodge; J Bartlett; J Toso; D Moody; Jim Tartaglia; W I Cox; E Paoletti; Kent J Weinhold
Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy.
Blood 1997;90(6):2406-16.
1997: M Girard; E Van Der Ryst; Françoise Barré-Sinoussi; P Nara; Jim Tartaglia; E Paoletti; C Blondeau; M Jennings; FC Verrier; B Meignier; PN Fultz
Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus.
Virology 1997;232(1):98-104.
1997: M Kawakita; G S Rao; J K Ritchey; David K Ornstein; MA Hudson; Jim Tartaglia; E Paoletti; P A Humphrey; T J Harmon; T L Ratliff
Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth.
Journal of the National Cancer Institute 1997;89(6):428-36.
1997: Charles B Stephensen; J Welter; S R Thaker; J Taylor; Jim Tartaglia; E Paoletti
Canine distemper virus (CDV) infection of ferrets as a model for testing Morbillivirus vaccine strategies: NYVAC- and ALVAC-based CDV recombinants protect against symptomatic infection.
Journal of virology 1997;71(2):1506-13.
1996: Sören Andersson; Barbro Mäkitalo; Rigmor Thorstensson; Genoveffa Franchini; Jim Tartaglia; K Limbach; E Paoletti; P Putkonen; Gunnel Biberfeld
Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys.
The Journal of infectious diseases 1996;174(5):977-85.
1996: B Fleury; G Janvier; G Pialoux; Florence Buseyne; M N Robertson; Jim Tartaglia; E Paoletti; Marie Paule Kieny; Jean-Louis Excler; Yves Rivière
Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160.
The Journal of infectious diseases 1996;174(4):734-8.
1996: M Myagkikh; S Alipanah; Phillip D Markham; Jim Tartaglia; E Paoletti; Robert C Gallo; Genoveffa Franchini; Marjorie Robert-Guroff
Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques.
AIDS research and human retroviruses 1996;12(11):985-92.
1996: L F Fries; Jim Tartaglia; J Taylor; E K Kauffman; B Meignier; E Paoletti; Stanley Plotkin
Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system.
Vaccine 1996;14(5):428-34.
1996: Genoveffa Franchini; J Benson; Robert C Gallo; E Paoletti; Jim Tartaglia
Attenuated poxvirus vectors as carriers in vaccines against human T cell leukemia-lymphoma virus type I.
AIDS research and human retroviruses 1996;12(5):407-8.
1996: E Beattie; E B Kauffman; H Martinez; M E Perkus; Bertram L Jacobs; E Paoletti; Jim Tartaglia
Host-range restriction of vaccinia virus E3L-specific deletion mutants.
Virus genes 1996;12(1):89-94.
1995: Genoveffa Franchini; Marjorie Robert-Guroff; Jim Tartaglia; A Aggarwal; Alash'Le Abimiku; J Benson; Phillip Markham; K Limbach; G Hurteau; J Fullen
Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques.
AIDS research and human retroviruses 1995;11(8):909-20.
1995: E Beattie; E Paoletti; Jim Tartaglia
Distinct patterns of IFN sensitivity observed in cells infected with vaccinia K3L- and E3L- mutant viruses.
Virology 1995;210(2):254-63.
1995: M E Perkus; Jim Tartaglia; E Paoletti
Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases.
Journal of leukocyte biology 1995;58(1):1-13.
1995: S Pincus; Jim Tartaglia; E Paoletti
Poxvirus-based vectors as vaccine candidates.
Biologicals : journal of the International Association of Biological Standardization 1995;23(2):159-64.
1995: M E Perkus; J Taylor; Jim Tartaglia; S Pincus; E B Kauffman; John A Tine; E Paoletti
Live attenuated vaccinia and other poxviruses as delivery systems: public health issues.
Annals of the New York Academy of Sciences 1995;754():222-33.
1995: Alash'Le Abimiku; Genoveffa Franchini; Jim Tartaglia; Kristine Aldrich; M Myagkikh; Phillip D Markham; P Chong; M Klein; M P Kieny; E Paoletti
HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques.
Nature medicine 1995;1(4):321-9.
1995: J Taylor; B Meignier; Jim Tartaglia; B Languet; J VanderHoeven; G Franchini; C Trimarchi; E Paoletti
Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species.
Vaccine 1995;13(6):539-49.
1995: Genoveffa Franchini; Jim Tartaglia; Phillip Markham; J Benson; J Fullen; M Wills; J Arp; Gregory A Dekaban; E Paoletti; Robert C Gallo
Highly attenuated HTLV type Ienv poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits.
AIDS research and human retroviruses 1995;11(2):307-13.
1995: SA Plotkin; M Cadoz; B Meignier; C Méric; Odile Leroy; Jean-Louis Excler; Jim Tartaglia; E Paoletti; E Gonczol; G Chappuis
The safety and use of canarypox vectored vaccines.
Developments in biological standardization 1995;84():165-70.
1995: E Paoletti; J Taylor; B Meignier; C Meric; Jim Tartaglia
Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC.
Developments in biological standardization 1995;84():159-63.
1995: E Beattie; K L Denzler; Jim Tartaglia; M E Perkus; E Paoletti; Bertram L Jacobs
Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene.
Journal of virology 1995;69(1):499-505.
1994: E Paoletti; Jim Tartaglia; J Taylor
Safe and effective poxvirus vectors--NYVAC and ALVAC.
Developments in biological standardization 1994;82():65-9.
1994: J Taylor; Jim Tartaglia; M Rivière; C Duret; B Languet; G Chappuis; E Paoletti
Applications of canarypox (ALVAC) vectors in human and veterinary vaccination.
Developments in biological standardization 1994;82():131-5.
1994: Jim Tartaglia; W I Cox; S Pincus; E Paoletti
Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC.
Developments in biological standardization 1994;82():125-9.
1993: Susan L Brockmeier; Kelly M Lager; Jim Tartaglia; M Riviere; E Paoletti; William L Mengeling
Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses.
Veterinary microbiology 1993;38(1-2):41-58.
1993: E Paoletti; Jim Tartaglia; W I Cox
Immunotherapeutic strategies for cancer using poxvirus vectors.
Annals of the New York Academy of Sciences 1993;690():292-300.
1993: W I Cox; Jim Tartaglia; E Paoletti
Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein.
Virology 1993;195(2):845-50.
1993: Jim Tartaglia; O Jarrett; J C Neil; P Desmettre; E Paoletti
Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL.
Journal of virology 1993;67(4):2370-5.
1992: Jim Tartaglia; W I Cox; J Taylor; M Perkus; M Riviere; B Meignier; E Paoletti
Highly attenuated poxvirus vectors.
AIDS research and human retroviruses 1992;8(8):1445-7.
1992: Kent J Weinhold; Jim Tartaglia; E Paoletti; B Graham; David H Schwartz; J McElrath; N Roberts; Geoffrey J Gorse
Specific activation strategies for amplification of low CTL signals.
AIDS research and human retroviruses 1992;8(8):1373.
1992: M Cadoz; A Strady; B Meignier; J Taylor; Jim Tartaglia; E Paoletti; Stanley Plotkin
Immunisation with canarypox virus expressing rabies glycoprotein.
Lancet 1992;339(8807):1429-32.
1992: M Riviere; Jim Tartaglia; M E Perkus; E K Norton; C M Bongermino; F Lacoste; C Duret; P Desmettre; E Paoletti
Protection of mice and swine from pseudorabies virus conferred by vaccinia virus-based recombinants.
Journal of virology 1992;66(6):3424-34.
1992: Jim Tartaglia; M E Perkus; J Taylor; E K Norton; J C Audonnet; W I Cox; S W Davis; J van der Hoeven; B Meignier; M Riviere
NYVAC: a highly attenuated strain of vaccinia virus.
Virology 1992;188(1):217-32.
1992: J Taylor; R Weinberg; Jim Tartaglia; C Richardson; G Alkhatib; D Briedis; M Appel; E Norton; E Paoletti
Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins.
Virology 1992;187(1):321-8.
1991: J Taylor; S Pincus; Jim Tartaglia; C Richardson; G Alkhatib; D Briedis; M Appel; E Norton; E Paoletti
Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge.
Journal of virology 1991;65(8):4263-74.
1991: E Beattie; Jim Tartaglia; E Paoletti
Vaccinia virus-encoded eIF-2 alpha homolog abrogates the antiviral effect of interferon.
Virology 1991;183(1):419-22.
1990: Jim Tartaglia; S Pincus; E Paoletti
Poxvirus-based vectors as vaccine candidates.
Critical reviews in immunology 1990;10(1):13-30.